MONTREAL -- Geographic atrophy (GA) had a similar response to the complement inhibitor pegcetacoplan (Syfovre) whether concurrent with neovascular age-related macular degeneration (nAMD) or alone, data from a retina clinical network showed.
Compared with pretreatment status, the rate of GA progression, reflected in loss of retinal pigment epithelium (RPE), slowed by 23% in eyes with GA alone and 40% in eyes with concurrent nAMD. Photoreceptor (PR) loss also slowed in both types of eyes, but eyes with nAMD had numerically greater protection (-58% vs -41%).
Eyes that progressed more rapidly in the 12 months before initiation of pegcetacoplan remained faster after treatment started but the rate of progression slowed, reported Hasenin Al-khersan, MD, of the Retina Group of Florida in Fort Lauderdale, at the American Society of Retina Specialists (ASRS) meeting.
"We saw that rates of atrophy progression were similar pre-pegcetacoplan treatment in eyes with GA alone and those with GA and neovascular AMD," said Al-khersan. "Subsequent to the initiation of pegcetacoplan, we see a reduction in photoreceptor and RPE atrophy rates over the 12 months in both cohorts, with larger numerical effects in the combined-disease cohort, indicating that pegcetacoplan reduces atrophy progression in those with neovascular AMD and concurrent atrophy."
